The news: Healthcare AI company Abridge is pushing past medical documentation into a wider stack of clinical and pharmaceutical workflows, and it just signed deals with Nvidia and Eli Lilly to support the effort.

• New features for clinicians now surface relevant patient history, provide guideline-based decision support, answer physicians’ questions, and automatically generate documentation and billing codes needed for reimbursement.
• With Nvidia, Abridge will develop a system trained directly on doctor-patient exchanges rather than fine-tuning a generic AI model for healthcare use.
• The Lilly tie-up is focused on identifying clinical trial candidates, particularly for diseases where biomarkers and risk indicators can appear years before diagnosis, but patients remain difficult to detect and recruit.

Why it matters: In a crowded healthcare AI market, Abridge is betting that the logos on its partner list will do some of the selling. Tying up with two trillion-dollar companies gives Abridge a credibility shortcut as health systems weigh which tools merit investment.

Hospitals are evaluating dozens, if not hundreds, of competing AI platforms, from tech giants like Microsoft and OpenAI to healthcare-focused players such as Suki, Ambience, and OpenEvidence, as well as electronic health record (EHR) leader Epic. Abridge doesn’t appear to have formal partnerships with other pharma companies beyond Lilly, but Lilly’s participation suggests drugmakers see value in integrating AI-generated clinical insights into broader efforts aimed at bringing new treatments to market.

Implications for healthcare AI companies: The bar is rising. As buyers move beyond pilot programs to full-scale implementation, they ultimately demand measurable ROI, real-world evidence, proven case studies, and strong vendor support. Strategic partnerships between tech firms and healthcare organizations that combine AI capabilities with deep industry expertise to develop scalable solutions are becoming a differentiator.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.